Marksans Pharma Limited
5,579words
0turns
0analyst exchanges
0executives
Key numbers — 40 extracted
8.3%
he challenging environment, we had a revenue M A N A G I N G D I R E C TO R A N D C E O growth of 8.3% YoY. Our business remained resilient. We will continue to focus on investment in R&D and manufactu
8.3 %
s the regions and we are well-positioned to take advantage of these new opportunities.” 1,490.8 +8.3 % (YoY) 258.9 (23.8%) (YoY) 186.8 (21.7%) (YoY) FY22 Revenue (₹ cr.) FY22 EBITDA (₹ cr.) FY2
23.8%
e well-positioned to take advantage of these new opportunities.” 1,490.8 +8.3 % (YoY) 258.9 (23.8%) (YoY) 186.8 (21.7%) (YoY) FY22 Revenue (₹ cr.) FY22 EBITDA (₹ cr.) FY22 PAT (₹ cr.) 349.3 (
21.7%
take advantage of these new opportunities.” 1,490.8 +8.3 % (YoY) 258.9 (23.8%) (YoY) 186.8 (21.7%) (YoY) FY22 Revenue (₹ cr.) FY22 EBITDA (₹ cr.) FY22 PAT (₹ cr.) 349.3 (Mar'22) Cash (₹ cr.)
₹418.0
₹ cr.) 4 Q4 & FY22 Highlights 5 Financial Highlights Q4FY22 • • • • Operating revenue was ₹418.0 cr. compared to ₹330.2 cr. in Q4FY21, an increase of +26.6% YoY Gross profit was ₹206.4 cr., with g
₹330.2
ghlights 5 Financial Highlights Q4FY22 • • • • Operating revenue was ₹418.0 cr. compared to ₹330.2 cr. in Q4FY21, an increase of +26.6% YoY Gross profit was ₹206.4 cr., with gross margin at 49.4% E
26.6%
Y22 • • • • Operating revenue was ₹418.0 cr. compared to ₹330.2 cr. in Q4FY21, an increase of +26.6% YoY Gross profit was ₹206.4 cr., with gross margin at 49.4% EBITDA was ₹63.6 cr., with EBITDA mar
₹206.4
evenue was ₹418.0 cr. compared to ₹330.2 cr. in Q4FY21, an increase of +26.6% YoY Gross profit was ₹206.4 cr., with gross margin at 49.4% EBITDA was ₹63.6 cr., with EBITDA margin at 15.2% PBT was ₹52.6 cr
49.4%
₹330.2 cr. in Q4FY21, an increase of +26.6% YoY Gross profit was ₹206.4 cr., with gross margin at 49.4% EBITDA was ₹63.6 cr., with EBITDA margin at 15.2% PBT was ₹52.6 cr., while PAT stood at ₹29.7 cr.
₹63.6
Y21, an increase of +26.6% YoY Gross profit was ₹206.4 cr., with gross margin at 49.4% EBITDA was ₹63.6 cr., with EBITDA margin at 15.2% PBT was ₹52.6 cr., while PAT stood at ₹29.7 cr. Business Highligh
15.2%
ross profit was ₹206.4 cr., with gross margin at 49.4% EBITDA was ₹63.6 cr., with EBITDA margin at 15.2% PBT was ₹52.6 cr., while PAT stood at ₹29.7 cr. Business Highlights- FY22 • • • Acquired Acce
₹52.6
₹206.4 cr., with gross margin at 49.4% EBITDA was ₹63.6 cr., with EBITDA margin at 15.2% PBT was ₹52.6 cr., while PAT stood at ₹29.7 cr. Business Highlights- FY22 • • • Acquired Access Healthcare fo
Advertisement